Pinkal Desai, MD, MPH, Weill Cornell Medical College, New York City, NY, discusses the results of a Phase I study of the CD123 natural killer (NK) cell engager SAR443579 in patients with relapsed/refractory acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) or high-risk myelodysplastic syndromes (HR-MDS; NCT05086315). The study reported encouraging efficacy results and was very well tolerated. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть